

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hansoh Pharmaceutical Group Company Limited**

**翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 3692)**

### **VOLUNTARY ANNOUNCEMENT**

### **SHARE PURCHASE PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME**

This announcement is made by Hansoh Pharmaceutical Group Company Limited (the “**Company**”) on a voluntary basis.

Reference is made to the restricted share unit scheme (the “**Scheme**”) conditionally approved and adopted by the Company on May 27, 2019, a summary of the principal terms of the Scheme is set out in the section headed “Statutory and General Information – D. Post-IPO RSU Scheme” in Appendix IV of the prospectus of the Company dated May 31, 2019 (the “**Prospectus**”). Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as ascribed to them in the Prospectus.

The Company was informed by the RSU Trustee that it had purchased an aggregate of 2,000,000 Shares (the “**Share Purchase**”) on the market for the purpose of the Scheme. Details of the Share Purchase and the latest information about the Shares held by the RSU Trustee are as follows:

|  |                                       |
|--|---------------------------------------|
| Trade dates:   | December 2, 2021 to December 31, 2021 |
| Settlement dates:  | December 6, 2021 to January 4, 2022   |
| Total number of Shares purchased:  | 2,000,000 Shares                      |
| Percentage of the Shares purchased to the total number of issued Shares as at the date of this announcement: | Approximately 0.03%                   |

Average consideration per Share (excluding all related expenses, including but not limited to transaction levy, brokerage, tax): Approximately HK\$18.0307

Total consideration of Shares purchased (excluding all related expenses, including but not limited to transaction levy, brokerage, tax): HK\$36,061,300

Balance of Shares held by the RSU Trustee:

– *Prior to the Share Purchase* 2,000,000 Shares

– *Immediately after the Share Purchase* 4,000,000 Shares

Subject to and in compliance with the requirements of the Listing Rules, the Board will from time to time review and determine at its absolute discretion such number of the RSU(s) to be awarded to the Selected Person(s) with such vesting conditions as it may deem appropriate and the number of Shares to be further purchased from the market under the Scheme.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, December 31, 2021

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*